A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.

@article{Ryan2006API,
  title={A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.},
  author={Christopher W. Ryan and M. Eileen Dolan and Bruce B. Brockstein and Roger E McLendon and Shannon M. Delaney and Brian L Samuels and Edem S. Agamah and Everett E. Vokes},
  journal={Cancer chemotherapy and pharmacology},
  year={2006},
  volume={58 5},
  pages={634-9}
}
PURPOSE Tumor resistance to alkylating agents such as carmustine (BCNU) has been found to be associated with intracellular expression of O6-methylguanine-DNA methyltransferase (MGMT). Administration of O6-benzylguanine (O6-BG), a substrate that inactivates MGMT, may help overcome chemotherapy resistance. We performed a phase II study to explore the activity of O6-BG in combination with BCNU in patients with advanced soft tissue sarcoma. EXPERIMENTAL DESIGN Informed consent was obtained from… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Special Technologies for Ex Vivo Analysis of Cancer.

Cancer control : journal of the Moffitt Cancer Center • 2015
View 1 Excerpt

Similar Papers

Loading similar papers…